C4 Therapeutics, Inc. - 10-Q Filing

C4 Therapeutics reports Q3 2026 financial position and updates on collaborative milestone agreements with Roche, Merck KGaA, and Betta Pharmaceuticals.

SEC EDGAR ·

Tickers: $CCCC

Read the full article at SEC EDGAR

More Regulatory news